Research and Markets: Renal Denervation Market - Current Situation Future ... - Business Wire (press release) |
|
|
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/4fkjfc/renal_denervation) has announced the addition of the "Renal Denervation Market - Current Situation & Future Outlook" report to their offering.
“Renal Denervation Market - Current Situation & Future Outlook”
Renal artery denervation, a new device-based therapeutic paradigm for managing treatment resistant hypertension, has come of age and is attracting an unprecedented gold rush from serial medical device entrepreneurs.
Medtronic's acquisition of Ardian for $800 million plus $500 million more in milestone payments in January 2011 signaled the dawning of a new era of catheter-based renal denervation systems.
Results of the Symplicity HTN-1 and Symplicity HTN-2 trials have generated considerable interest among physicians, patients, medical device entrepreneurs, and the investment community.
The market, although still in the inception phase, has already attracted heavy hitters with Covidien paying $230 Million for Maya Medical' OneShot renal denervation system, St. Jude launching its EnligHTN renal denervation system in Europe in May 2012 and Boston Scientific diverting its R&D resources for a first-in-man with a new device before the end of 2012.
Renal denervation is a catheter-based therapy that uses either radiofrequency or ultrasound energy to disrupt the renal arteries sympathetic nerves whose hyperactivity may lead to treatment-resistant hypertension.
Renal denervation systems are perhaps the hottest medical device innovation space this year as they offer a complementary approach to the management of resistant hypertension that was not available before.
Renal Denervation Market report attempts to answer some important questions regarding the fast evolving market by examining Leading companies technologies, product offerings, market shares. The report offers a credible forecast to 2016.
Companies Mentioned
- Ardian
- Boston Scientific
- CardioSonic
- Covidien
- Kona Medical
- Maya Medical
- Mercator MedSystems
- Medtronic
- ReCor Medical
- St. Jude Medical
- Vessix Vascular
For more information visit http://www.researchandmarkets.com/research/4fkjfc/renal_denervation
|
Mayo Clinic children's specialties get top ranking - Post-Bulletin |
|
|
By Post-Bulletin staff
Mayo Clinic has ranked among the best Midwest children's hospitals in the 2012-2013 U.S. New & World Reports Best Children's Hospitals rankings.
According to the clinic, Mayo was the only Minnesota hospital to rank in all 10 pediatric specialties, including cancer, cardiology and heart surgery, diabetes and endocrinology, gastroenterology, neonatology, nephrology, neurology and neurosurgery, orthopedics, pulmonology and urology.
Dr. Ann Reed, chair of the Mayo Clinic Children's Center, said employees work diligently "to make each patient's experience the best it can be."
|
|
Positive results from Amgen Sensipar/Mimpara Phase 3 trial for HPT, CKD - News-Medical.net |
|
|
7e749cb5-1e79-4293-8d80-51b3f9cde1c4|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Angina, Arthritis, Biotechnology, Bone, Calcium, Cancer, Carcinoma, Cell, Dialysis, Diarrhea, Heart Failure, Hormone, Hyperparathyroidism, Hyperthyroidism, Hypocalcemia, Kidney Disease, Muscle, Nausea, Nephrology, Pain, Parathyroidectomy, Phosphorous, Placebo, Rheumatoid Arthritis, Vitamin D, Vomiting
|
Amgen drug Sensipar fails to meet trial goal - Reuters UK |
|
|
Fri Jun 8, 2012 3:03pm BST
(Reuters) - Amgen Inc said on Friday a late-stage trial of its drug Sensipar failed to reduce the risk of death and cardiovascular problems in patients with a complication of kidney disease.
The goal of the study was to show a reduction in the risk of death, heart attack, unstable angina or heart failure in patients with chronic kidney disease who were receiving dialysis.
Although patients taking Sensipar experienced fewer events, the results were not statistically significant and the trial did not meet its goal, Amgen said in a statement.
Sensipar is approved to treat secondary hyperparathyroidism, a condition in which the body produces too much parathyroid hormone, a natural substance needed to control the amount of calcium in the blood. It can be a consequence of kidney failure.
Sensipar has been shown to lower calcium levels in the blood of patients who are on long-term dialysis for kidney disease. Amgen hoped to show it reduced death and heart risks.
Amgen's shares fell 22 cents, or 0.3 percent, to $68.88 in early trading on Nasdaq.
(Reporting By Toni Clarke; editing by M.D. Golan)
|
|